These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26495783)

  • 1. Combination of Telmisartan and Linagliptin Preserves Pancreatic Islet Cell Function and Morphology in db/db Mice.
    Zhao S; Chan LK; Chen L; Cheng TW; Klein T; Leung PS
    Pancreas; 2016 Apr; 45(4):584-92. PubMed ID: 26495783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice.
    Chen L; Klein T; Leung PS
    Curr Mol Med; 2012 Sep; 12(8):995-1004. PubMed ID: 22804249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan attenuates fatty-acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells.
    Saitoh Y; Hongwei W; Ueno H; Mizuta M; Nakazato M
    Diabetes Metab; 2009 Nov; 35(5):392-7. PubMed ID: 19713141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.
    Tsuprykov O; Ando R; Reichetzeder C; von Websky K; Antonenko V; Sharkovska Y; Chaykovska L; Rahnenführer J; Hasan AA; Tammen H; Alter M; Klein T; Ueda S; Yamagishi SI; Okuda S; Hocher B
    Kidney Int; 2016 May; 89(5):1049-1061. PubMed ID: 27083282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes.
    Cheng Q; Law PK; de Gasparo M; Leung PS
    J Pharmacol Exp Ther; 2008 Dec; 327(3):683-91. PubMed ID: 18787107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice.
    Shiota A; Shimabukuro M; Fukuda D; Soeki T; Sato H; Uematsu E; Hirata Y; Kurobe H; Maeda N; Sakaue H; Masuzaki H; Shimomura I; Sata M
    Cardiovasc Diabetol; 2012 Nov; 11():139. PubMed ID: 23137106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
    Alter ML; Ott IM; von Websky K; Tsuprykov O; Sharkovska Y; Krause-Relle K; Raila J; Henze A; Klein T; Hocher B
    Kidney Blood Press Res; 2012; 36(1):119-30. PubMed ID: 23171828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.
    Min LJ; Mogi M; Shudou M; Jing F; Tsukuda K; Ohshima K; Iwanami J; Horiuchi M
    Hypertension; 2012 May; 59(5):1079-88. PubMed ID: 22454480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.
    Souza-Mello V; Gregório BM; Cardoso-de-Lemos FS; de Carvalho L; Aguila MB; Mandarim-de-Lacerda CA
    Clin Sci (Lond); 2010 Jun; 119(6):239-50. PubMed ID: 20415664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension.
    Chaykovska L; Alter ML; von Websky K; Hohmann M; Tsuprykov O; Reichetzeder C; Kutil B; Kraft R; Klein T; Hocher B
    J Hypertens; 2013 Nov; 31(11):2290-8; discussion 2299. PubMed ID: 24077249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic ultrastructural enhancement due to telmisartan plus sitagliptin treatment in diet-induced obese C57BL/6 mice.
    Souza-Mello V; Gregório BM; Relvas-Lucas B; da Silva Faria T; Aguila MB; Mandarim-de-Lacerda CA
    Pancreas; 2011 Jul; 40(5):715-22. PubMed ID: 21602737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion.
    Washida K; Ihara M; Nishio K; Fujita Y; Maki T; Yamada M; Takahashi J; Wu X; Kihara T; Ito H; Tomimoto H; Takahashi R
    Stroke; 2010 Aug; 41(8):1798-806. PubMed ID: 20595663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of angiotensin II type 1 receptor blocker on islet of diabetic db/db mice].
    Shao JQ; Iwashita N; Du H; Wang YY; Zhao M; Wang J; Watada H; Kawamori R
    Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):306-10. PubMed ID: 17637271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute regulation of pancreatic islet microcirculation and glycaemia by telmisartan and ramipril: discordant effects between normal and type 2 diabetic rats.
    Olverling A; Huang Z; Nyström T; Sjöholm Å
    Clin Sci (Lond); 2013 Nov; 125(9):433-8. PubMed ID: 23713675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telmisartan, an angiotensin II type 1 receptor blocker, prevents the development of diabetes in male Spontaneously Diabetic Torii rats.
    Hasegawa G; Fukui M; Hosoda H; Asano M; Harusato I; Tanaka M; Shiraishi E; Senmaru T; Sakabe K; Yamasaki M; Kitawaki J; Fujinami A; Ohta M; Obayashi H; Nakamura N
    Eur J Pharmacol; 2009 Mar; 605(1-3):164-9. PubMed ID: 19171132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II Type 1 receptor antagonism mediates uncoupling protein 2-driven oxidative stress and ameliorates pancreatic islet beta-cell function in young Type 2 diabetic mice.
    Chu KY; Leung PS
    Antioxid Redox Signal; 2007 Jul; 9(7):869-78. PubMed ID: 17508912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells.
    Liang J; Leung KK; Lam SY; Leung PS
    Diabetes Obes Metab; 2012 Sep; 14(9):842-51. PubMed ID: 22519909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.
    Iwanami J; Mogi M; Tsukuda K; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
    J Hypertens; 2010 Aug; 28(8):1730-7. PubMed ID: 20498620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity.
    Toyama K; Nakamura T; Kataoka K; Yasuda O; Fukuda M; Tokutomi Y; Dong YF; Ogawa H; Kim-Mitsuyama S
    Biochem Biophys Res Commun; 2011 Jul; 410(3):508-13. PubMed ID: 21679694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice.
    Shao J; Iwashita N; Ikeda F; Ogihara T; Uchida T; Shimizu T; Uchino H; Hirose T; Kawamori R; Watada H
    Biochem Biophys Res Commun; 2006 Jun; 344(4):1224-33. PubMed ID: 16650382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.